Invivyd Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
IVVD$0.57-3.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | Nine Months Ended September 30, | |
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(151,482) | $(124,989) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 16,731 | 14,341 |
| Net amortization of premiums and accretion of discounts on marketable securities | — | (6,256) |
| Amortization of operating lease right-of-use assets | 1,215 | 1,152 |
| Depreciation expense | 382 | 360 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (8,154) | — |
| Inventory | (23,391) | — |
| Prepaid expenses and other current assets | 15,311 | (292) |
| Other non-current assets | (7,277) | 4 |
| Accounts payable | 9,714 | 7,685 |
| Accrued expenses | 16,032 | (5,452) |
| Operating lease liabilities | (1,247) | (1,159) |
| Other current liabilities | (15) | (18) |
| Other non-current liabilities | (700) | 700 |
| Net cash used in operating activities | (132,881) | (113,924) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | — | (91,202) |
| Maturities of marketable securities | — | 294,583 |
| Purchases of property and equipment | (145) | (615) |
| Net cash (used in) provided by investing activities | (145) | 202,766 |
| Cash flows from financing activities: | ||
| Proceeds from exercises of stock options | 285 | 709 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 191 | 196 |
| Proceeds from issuance of common stock, net of issuance costs | 39,285 | — |
| Payments for offering costs | (507) | — |
| Payments for repurchases of unvested restricted common stock | — | (1) |
| Net cash provided by financing activities | 39,254 | 904 |
| Net (decrease) increase in cash and cash equivalents | (93,772) | 89,746 |
| Cash and cash equivalents at beginning of period | 200,641 | 92,076 |
| Cash and cash equivalents at end of period | $106,869 | $181,822 |
| Supplemental disclosure of cash flow information | ||
| Deferred offering costs in accrued expense | $35 | $— |
| Deferred offering costs in accounts payable | $40 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.